Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    21
    ...
ATC Name B/G Ingredients Dosage Form Price
R06AX22 EBASTINE ARROW G Ebastine - 10mg 10mg Tablet, coated 524,099 L.L
L01EF01 PAPILLIO G Palbociclib - 125mg 125mg Capsule, hard L.L
A02BC01 OMEPRAL G Omeprazole - 40mg 40mg Capsule, delayed release 499,142 L.L
A07EC02 SALCROZINE G Mesalazine - 1g 1g Tablet, gastroresistant 4,073,187 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 174,062 L.L
C03CA01 FUROSEMIDE RENAUDIN G Furosemide - 250mg/25ml 250mg/25ml Injectable solution 1,791,342 L.L
C09CA03 ARBITEN 160 G Valsartan - 160mg 160mg Tablet 544,256 L.L
C10AA05 ATORVASTATINE ARROW GENERQUES G Atorvastatin - 40mg 40mg Tablet, coated 564,414 L.L
D07XC03 ELICA M G Mometasone furoate - 0.1%, Miconazole nitrate - 2% Cream 459,594 L.L
G04BE08 RAVANA G Tadalafil - 20mg 20mg Tablet 500,421 L.L
J01CR05 YANOVEN G Piperacillin (sodium) - 2g, Tazobactam (sodium) - 0.25g Injectable powder for solution 830,623 L.L
J01MA02 CIPROFLOXACINE PANPHARMA G Ciprofloxacin - 200mg/100ml 200mg/100ml Injectable solution 4,914,432 L.L
M01AE02 NOPAIN DS G Naproxen (sodium) - 500mg 500mg Tablet, film coated 235,172 L.L
N02AJ13 TRAMADOL/PARACETAMOL ARROW LAB G Tramadol - 37.5mg, Paracetamol - 325mg Tablet, coated 205,608 L.L
N06AB06 SERTRALINE BIOGARAN G Sertraline HCl - 50mg 50mg Capsule 520,067 L.L
R06AX26 EXOFEN G Fexofenadine HCl - 120mg 120mg Tablet, film coated 287,582 L.L
A02BC01 RISEK G Omeprazole - 40mg 40mg Capsule, enteric coated 522,755 L.L
A10BK03 EMPAZA G Empagliflozin - 10mg 10mg Tablet, film coated 1,740,724 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 174,062 L.L
C03CA01 FUROSEMIDE S.A.L.F. G Furosemide - 250mg/25ml 250mg/25ml Injectable solution 919,188 L.L
C09CA03 TABUVAN G Valsartan - 160mg 160mg Tablet, film coated 544,256 L.L
C10AA05 EMITOR G Atorvastatin - 40mg 40mg Tablet, film coated 1,060,292 L.L
D07XC03 ELICASAL G Mometasone furoate - 1mg/g, Salicylic acid - 50mg/g Ointment 462,282 L.L
G04BE08 TADALAGEN G Tadalafil - 20mg 20mg Tablet, film coated 1,032,839 L.L
J01MA02 CIPROLON 200 G Ciprofloxacin (lactate) - 200mg/100ml 200mg/100ml Injectable solution 686,704 L.L
N03AX18 LACOSAMIDE/GENEPHARM G Lacosamide - 50mg 50mg Tablet 614,136 L.L
N06AB06 SOLOTIK G Sertraline HCl - 50mg 50mg Tablet, film coated 357,462 L.L
R02A ALFA-AMYLASE BGR CONSEIL G Alpha-Amylase - 200U.CEIP/ml 200U.CEIP/ml Syrup 384,339 L.L
R06AX26 FENADEX 120 G Fexofenadine HCl - 120mg 120mg Tablet, film coated 295,645 L.L
A02BC01 ESELAN G Omeprazole (sodium) - 40mg 40mg Injectable lyophilised powder for solution 2,073,549 L.L
    ...
    21
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025